Navigation Links
JumpStart Invests $250,000 in Milo Biotechnology
Date:2/14/2012

CLEVELAND, Feb. 14, 2012 /PRNewswire/ -- Milo Biotechnology will receive $250,000 from JumpStart Inc., a nonprofit investing intensive business assistance and some capital into early stage Northeast Ohio-based tech companies.  A clinical stage startup developing a therapy to increase muscle strength and improve the quality of life of muscular dystrophy patients, Milo is the 61st company in JumpStart's portfolio.  "There are limited treatment options for muscular dystrophy and approved therapies are inadequate or can cause significant side effects," says JumpStart's Mike Lang. "Since most muscular dystrophy patients are children, the medical community is interested in a safer and more targeted therapy."

Milo Biotechnology's lead product is an adeno-associated virus (AAV) delivered follistatin protein.  Follistatin inhibits the activity of myostatin, a protein that impedes muscle differentiation and growth.  That makes follistatin a very potent stimulator of muscle growth and prevention of muscle scarring after injury.  "The translational research team at the Research Institute at Nationwide Children's Hospital has harnessed the power of follistatin and increased its specificity for muscle," explains Al Hawkins, CEO of Milo Biotechnology and CEO-in-Residence at BioEnterprise in Cleveland. "The efficacy and safety results thus far have been remarkable." Pre-clinical studies in mice and non-human primates demonstrated considerable increases in muscle size and strength.  FDA approved the investigators' IND in October 2011 and a clinical trial evaluating the safety and efficacy of Milo's follistatin therapy began last month at Columbus-based Nationwide Children's Hospital, where the technology was developed.  The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body myositis.

Milo Biotechnology was founded by Hawkins and one of the lead inventors of the follistatin technology, Brian Kaspar, PhD. 

MILO BIOTECHNOLOGY  Milo Biotechnology is a Cleveland-based company dedicated to improving the lives of patients with neuromuscular diseases.  Milo's early clinical stage follistatin program, exclusively licensed from Nationwide Children's Hospital, is designed to increase muscle size and strength.

JUMPSTART INC  JumpStart Inc. accelerates the successes of entrepreneurs, their companies, and the ecosystems supporting them. JumpStart has given intensive business assistance to more than 400 entrepreneurial clients and invested in 61 early stage Northeast Ohio companies. For more information, visit www.jumpstartinc.org and follow @JumpStartInc on Twitter.


'/>"/>
SOURCE JumpStart Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
2. Lockheed Martin Invests in Smart Grid Research and Development at Penn State University
3. Burrill & Company Invests in Taiwan Liposome Company
4. University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer
5. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
6. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
7. BioCrossroads Indiana Seed Fund Invests in Vaccine Biotech Company
8. BR Ventures Invests in Semprae Laboratories
9. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
10. Federal grant invests in nanostructured super materials
11. BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... Dec. 8, 2016  Soligenix, Inc. (OTCQB: SNGX) ... focused on developing and commercializing products to treat ... need, announced today the long-term follow-up data from ... a first-in-class Innate Defense Regulator (IDR), in the ... neck cancer patients undergoing chemoradiation therapy (CRT).  The ...
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/7/2016)... ... 07, 2016 , ... A new study published in the ... treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for ... blood sampling may improve the value of a blood-based test.” The study was ...
Breaking Biology Technology:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has ... using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer storage ... ... ... Setting up ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
Breaking Biology News(10 mins):